FindTrial
Sign In

Study comparing short acting and long acting forms of drug used for increasing the uterine strength after surgical delivery of baby from mother.

A prospective randomised double-blind study comparing Oxytocin vs Carbetocin as First-line Uterotonic Agent during Caesarean Section.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/10/046407
Enrollment
240
Registered
2022-10-12
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O998- Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium

Interventions

Intervention1: Carbetocin: Carbetocin 100 mcg IV Control Intervention1: Oxytocin: Oxytocin 3 U IV followed by 3 U per hour in 500ml RL. Two more boluses of 3 U oxytocin if retraction not good at 3 min

Sponsors

Dr Gita Nath
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting for elective or emergency cesarean section under spinal anesthesia

Exclusion criteria

Exclusion criteria: Allergy to carbetocin or oxytocin Any hemodynamic instability in the preoperative period Seizures

Design outcomes

Primary

MeasureTime frame
Need for second line uterotonic Timepoint: T1-after first line uterotonic—

Secondary

MeasureTime frame
To compare the hemodynamic effects of carbetocin and oxytocin in parturients coming for elective and emergency caesarean surgeries Timepoint: T1-5min after spinal T2-10min after spinal T3-15min after spinal T4-20min after spinal T5-25min after spinal T6-30min after spinal T7,8,9,10,11,12....EVERY 5min till end of surgery;Assessment of uterine tone by the surgeon on a scale of 0 to 10, 3 minutes and 10 minutes after delivery of babyTimepoint: T1-3 min After delivery of baby T2-10 min After delivery of baby;To compare the adverse effects of Carbetocin and Oxytocin on the parturientTimepoint: T1—

Countries

India

Contacts

Public ContactDr K Sailaja

Rainbow Childrens Hospital

sailu_k_78@yahoo.co.in07093322303

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026